

Studies on hospital acquired infections began more than 150
years ago with Ignaz Semmelweis and Florence Nightingale and contributed to the
advance of microbiologic and prophylactic actions in hospital environments.
Despite the increase of asepsis practices, hospital infections are still
considered a public health concern.
Many studies show that bio-aerosols
(micro-organism conglomerates in suspension in the air) play an important role
on the acquisition of infections being calculated as responsible for 10 to 20%
of those cases. The pathogens can be sprayed in many ways, via natural or forced
ventilation system, water spray, skin scales released by patients and medical
staff, coughing and sneezing. Studies also show that surgical staff members can
liberate between 1,500 to 50,000 bacteria per minute and those pathogens may
stay in suspension in the air for long periods of time. Studies reveal that 80
to 90% of all surgical wound infections are related to bad air quality and that
cleaner air translates into in lower infection risk.
Hospital infections not only result in high financial cost but also in high number of lost lives. Therefore, better than the clinical treatment itself, the prevention of hospital infections is the best strategy as being cheaper and more effective.
The annual cost of
treatment and hospitalization in England accounts for £1bn. According to the NAO
(National Audit Office) 2000 report, the NHS could have saved £150m if
preventive actions involving hospital hygiene and infection control had been
taken.
Staphylococcus
“Staphylococus aureus” is the most common bacteria in hospital infections across
the world and are especially linked to surgical wound infections that
represent 11% of all nosocomial infections in England.
Other bacterial pathogens have high relevance in airborne transmitted diseases and are well studied like the “Streptococcus spp” and “Pseudomonas aeruginosa”. Airborne pathogens are commonly related to respiratory tract infections which correspond to 23% of all hospital infections in England.
Aspergillus
“Aspergillus spp” is the most common fungus acquired trough air transmission in
hospitals. The “conidius propagulus” small size allows it to be in suspension in
the air for long periods of time, remaining viable for months, even in low
humidity places. Studies estimate that 75% of the Invasive “Aspergillosis” cases
result in death, especially due to the difficulty in diagnosing it. The daily
therapy cost is extremely high over £701, resulting in an average therapy cost
of £ 9.814(*) per patient. The therapy cost of just one invasive “Aspergillosis”
patient is approximately equivalent to 60 Airfree units.
*considering a 70 kg patient. Approximate cost of AWP (of Lamb)
is US$188 per 50 mg vial. Typical dose is 5.0 mg/kg/day. Estimated daily cost
per patient $ 1,316.
Airfree air purifier is proven to drastically reduce the
airborne microbial charge. In many microbiologic tests in real life conditions
performed by ISO 17025 certified independent laboratories, Airfree airborne
bacterial and fungal charge reduction in the environment is close to 90%.
Airfree reduces toxic Ozone as well. The extraordinary efficiency of patented
Airfree technology combines excellent thermo dynamics in conjunction with the
high efficiency of its ceramic core that captures and incinerates airborne
microorganisms at temperatures around 400 F. In fact, just 105.8F is required to
denaturize a series of thermo-sensitive proteins found in many cell regions,
especially in the nucleus. Independent tests show that Airfree can reduce up to
96% of the number of airborne bacteria and fungus in 500 sq ft contaminated
rooms with people working in it.
Destroys micro-organisms regardless of its virulence and size
Reduces toxic ozone
Totally silent, does not disturb patients
No maintenance required, no toxic filters to replace
No installation required, “plug in” unit
Low purchase and operating cost
It is reasonable to presume that given Airfree extraordinary airborne bacteria and fungus contamination reduction rate a wide number of infections could be avoided with the installation of Airfree.
Learn more about the Airfree P2000 indoor air purifier and see tests from independent laboratories.
Copyright © 2007 GIMIRA All rights reserved.
privacy policy -
shipping and returns -
contact - sitemap -
terms of use
indoor air purifiers for home